Weekly Digest – June 2025 Weekly Digest – June 2025 03 June 2025: Avenzo Therapeutics initiates Phase 1/2 clinical study of AVZO-1418, a potential best-in-class, novel EGFR/HER3 bispecific antibody drug conjugate Avenzo Therapeutics has initiated a Phase 1/2 clinical trial for […]